Twenty cases of silica stones (including a personal one, the first case ever observed – April 1952) are reviewed. Almost all of the patients had been taking magnesium trisilicate for several years, one up to 40 years. The average age of the patients was 54 years. There were 9 males and 1 female. The patients came from the following locations, given in chronological order: Beirut, Lebanon (1952); Stockholm, Sweden (1953, 1962); Houston, Tex., USA (1958, 1961); New York, N.Y., USA (1960); Johannesburg, South Africa (1964); London, UK (1973, 1982); Osaka, Japan (1978); Madrid, Spain (1978, 1981); and Torrance, Calif, USA (1984). 14 patients passed out the stones spontaneously. In 3 patients, the stone was formed in the left kidney. Bilateral renal stones were found in 2 patients. In 2 patients, they were removed from the left ureter and in 2 patients they were found in the bladder. The size of the stones varied between 2 mm and 3 cm, the weight from 8 mg to 3.6 g. The silica stone is of a relatively low radio density. Our case is the only one in whom the level of urinary silica was determined; it was of the order of 0.006% i.e. 1 mmol/l.

Keywords:
Silica, Silica stones, Urolithiasis
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.